Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996533 | 0.82 | NAAA (0.40) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL27853451 | 0.80 | NAAA (0.39) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL1002097 | 0.80 | LMNA (0.41) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL28103946 | 0.80 | NAAA (0.39) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL4450857 | 0.79 | NAAA (0.41) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL8342617 | 0.77 | ALDH1A1 (0.43) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL17083541 | 0.77 | ALDH1A1 (0.48) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL259571 | 0.77 | ALDH1A1 (0.43) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL27787073 | 0.77 | NAAA (0.40) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL722286 | 0.77 | NAAA (0.43) | NAAAALDH1A1CYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-3860999-B9 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3860999-B1 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3625233-B9 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3625233-B9 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3625233-B1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3625233-B1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-3676247-B1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| WO-2018208557-A1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROP NOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-10085999-B1 | Beta-lactamase inhibitors and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280161-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | NAAA 44/4885ALDH1A1 1229/4885CYP1A2 399/4885 |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | NAAA 44/4885ALDH1A1 1229/4885CYP1A2 399/4885 |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, CMBL | NAAA 113/4885ALDH1A1 834/4885CYP1A2 593/4885 |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | NAAA 44/4885ALDH1A1 1229/4885CYP1A2 399/4885 |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | NAAA 103/4885ALDH1A1 830/4885CYP1A2 502/4885 |
| US-10085999-B1 | Beta-lactamase inhibitors and uses thereof | GAA, LCT, MGAM | NAAA 103/4885ALDH1A1 830/4885CYP1A2 502/4885 |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | NAAA 103/4885ALDH1A1 830/4885CYP1A2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.